Dynamic. Agile. Connected.

The healthcare market is evolving rapidly, are your brand strategies advancing with it?

The launch window is now 18-36 months, not 12-18 months for a manufacturer to break even

Blum, Karen. A Smart Strategic Plan For Navigating Big Pharma Changes. Specialty Pharmacy Continuum.
https://link.edgepilot.com/s/33f39894/kRd8e4qdsUeiAX-_n4wbTQ?u=https://www.specialtypharmacycontinuum.com/Operations-and-Management/Article/08-23/A-Smart-Strategic-Plan-For-Navigating-Big-Pharma-Changes/71165.August 28, 2023.
Accessed December 18, 2023.

Sixty - five percent of covered workers, including 20% of covered workers at small firms and 82% in large firms are enrolled in plans that are self - funded

Kaiser Family Foundation. 2022 Employer Health Benefits Survey. Kaiser Family Foundation.
https://www.kff.org/report-section/ehbs-2022-summary-of-findings/#:~:text=Sixty%2Dfive%20percent%20of%20covered,to%20the%20percentage%20last%20year.
October 27, 2022. Accessed December18, 2023.

Maximum Fair Price negotiations will cut years from peak value

Greenwalt, Luke. How the Inflation Reduction Act is Changing the Rules in Life Sciences–Pt. 2. IQVIA.
https://www.iqvia.com/locations/united-states/blogs/2023/09/how-the-inflation-reduction-act-is-changing-the-rules-in-life-sciences-p2
October 3, 2023. Accessed December 18, 2023

The new incentives created by the IRA will lead to a variety of alterations in manufacturers’ pricing behaviors

Arda,Nitzan, McClellan, Mark B., Drug Pricing Reform In The Inflation Reduction Act: What Are The Implications? Part 1. Health Affairs Forefront.
https://www.healthaffairs.org/content/forefront/drug-pricing-reform-inflation-reduction-act-implications-part-1.
December 14, 2022. Accessed December 18, 2023

How will this impact your brand?

Harnessing over a century of biopharma leadership experience to challenge the status quo.

We regularly engage with HCPs and key decision-makers, staying abreast of industry trends and the unmet needs of these influencers. Through these interactions we bring fresh perspectives and innovative ideas to our clients on how to capitalize on market events for their brand(s) while differentiating themselves from the competition.

  • Oncology
  • Immunology
  • Rare Disease
  • Neurology

  • Infectious disease
  • Ophthalmology
  • Psychiatry
  • Allergy
  • Cardiology

  • Rheumatology
  • Gastroenterology
  • Pulmonology
  • Hematology
  • Otolaryngology

  • Dermatology
  • Orthopedics
  • Vaccines
  • Reproductive endocrinology
  • Nephrology

  • Endocrinology
  • Gynecology
  • Obesity
  • Urology
  • Aesthetics

And, while every therapeutic area comes with complexities, we know that each individual therapy can face its own set of unique market challenges. Across lifecycle stages from clinical to loss of exclusivity, we have helped teams successfully navigate the landscape including policy coverage, formulary access, reimbursement, and creative contracting scenarios that span:

icon-1

Autologous
Therapies

icon-2

Specialty
Injectables

icon-3

Infusions

icon-4

Diagnostics

icon-5

Gene Therapies

icon-6

Cell Therapies

icon-7

Devices

icon-8

Biosimilars

icon-9

Durable Medical
Equipment

Let our market experts reinvent your access strategy.